Asthma

Respiratory
270
Pipeline Programs
30
Companies
50
Clinical Trials
7 recruiting
36
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
37
2
82
2
82
65
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3588%
Small Molecule
513%
+ 292 programs with unclassified modality

On Market (36)

Approved therapies currently available

U
ACCUNEBApproved
albuterol sulfate
Unknown Company
inhalation2001
U
ALBUTEROLApproved
albuterol
Unknown Company
inhalation1995
U
ALBUTEROL SULFATEApproved
albuterol sulfate
Unknown Company
inhalation2017
U
ALVESCOApproved
ciclesonide
Unknown Company
inhalation2008
Novartis
ARCAPTA NEOHALERApproved
indacaterol maleate
Novartis
inhalation2011
Teva
ARMONAIR DIGIHALERApproved
fluticasone propionate
Teva
inhalation2017
Teva
ARMONAIR RESPICLICKApproved
fluticasone propionate
Teva
inhalation2017
Boehringer Ingelheim
ATROVENTApproved
ipratropium bromide
Boehringer Ingelheim
nasal1995
Boehringer Ingelheim
ATROVENT HFAApproved
ipratropium bromide
Boehringer Ingelheim
inhalation2004
U
BECLOMETHASONE DIPROPIONATEApproved
beclomethasone dipropionate
Unknown Company
inhalation2025
U
BUDESONIDEApproved
budesonide
Unknown Company
Corticosteroid [EPC]nasal2014
Teva
CINQAIRApproved
reslizumab
Teva
Interleukin-5 Antagonist [EPC]injection2016
Sandoz
CUTIVATEApproved
fluticasone propionate
Sandoz
topical1990
AstraZeneca
DALIRESPApproved
roflumilast
AstraZeneca
Phosphodiesterase 4 Inhibitor [EPC]oral2011
Regeneron
DUPIXENTApproved
dupilumab
Regeneron
Interleukin-4 Receptor alpha Antagonist [EPC]injection2017
AstraZeneca
FASENRAApproved
benralizumab
AstraZeneca
Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]injection2017
U
FLUTICASONE PROPIONATEApproved
fluticasone propionate
Unknown Company
topical2005
U
IPRATROPIUM BROMIDEApproved
ipratropium bromide
Unknown Company
nasal2003
U
OMNARISApproved
ciclesonide
Unknown Company
nasal2006
Teva
PROAIR DIGIHALERApproved
albuterol sulfate
Teva
inhalation2015
Teva
PROAIR HFAApproved
albuterol sulfate
Teva
inhalation2004
Teva
PROAIR RESPICLICKApproved
albuterol sulfate
Teva
inhalation2015
U
PROVENTIL-HFAApproved
albuterol sulfate
Unknown Company
inhalation1996
U
PROVOCHOLINEApproved
methacholine chloride
Unknown Company
inhalation1986
AstraZeneca
PULMICORTApproved
budesonide
AstraZeneca
inhalation1997
U
PULMICORT FLEXHALERApproved
budesonide
Unknown Company
Corticosteroid [EPC]inhalation2006
AstraZeneca
PULMICORT RESPULESApproved
budesonide
AstraZeneca
Corticosteroid [EPC]inhalation2000
Teva
QNASLApproved
beclomethasone dipropionate
Teva
nasal2012
Teva
QVAR 40Approved
beclomethasone dipropionate
Teva
inhalation2000
Teva
QVAR 80Approved
beclomethasone dipropionate
Teva
inhalation2000
U
RABEPRAZOLE SODIUMApproved
rabeprazole
Unknown Company
oral2015
U
RHINOCORTApproved
budesonide
Unknown Company
nasal1999
U
RHINOCORT ALLERGYApproved
budesonide
Unknown Company
nasal1999
U
ROFLUMILASTApproved
roflumilast
Unknown Company
Phosphodiesterase 4 Inhibitor [EPC]oral2022
U
VOLMAXApproved
albuterol sulfate
Unknown Company
oral1992
U
ZETONNAApproved
ciclesonide
Unknown Company
nasal2012

Competitive Landscape

53 companies ranked by most advanced pipeline stage

AstraZeneca
60 programs
5
2
14
2
CiclesonidePhase 41 trial
QIP interventionPhase 41 trial
BDA MDIPhase 31 trial
FASENRA(Benralizumab)Phase 3Monoclonal Antibody5 trials
BenralizumabPhase 3Monoclonal Antibody1 trial
+55 more programs
Active Trials
NCT00532922Completed310Est. Nov 2007
NCT04891978Completed857Est. Apr 2023
NCT04868500Completed49Est. Nov 2021
+75 more trials
Teva
49 programs
3
12
18
6
AirDuo DigihalerPhase 41 trial
BeclomethasonePhase 42 trials
Fluticasone propionate/salmeterolPhase 42 trials
QVARPhase 44 trials
QvarPhase 41 trial
+44 more programs
Active Trials
NCT01877954Completed2,654Est. Mar 2013
NCT01697722Completed815,377Est. Feb 2010
NCT01141439Completed815,377Est. Jul 2010
+63 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
45 programs
4
19
12
3
Ipratropium bromidePhase 41 trial
Salbutamol sulfate/Ipratropium bromidePhase 41 trial
ipratropium plus salbutamol UDVPhase 41 trial
Ba253BINEBPhase 31 trial
Berodual® Respimat®, low dosePhase 31 trial
+40 more programs
Active Trials
NCT02392481Completed69Est. Jan 2017
NCT02489981Completed359Est. Sep 2017
NCT03188120Completed193Est. Nov 2018
+42 more trials
Novartis
NovartisBASEL, Switzerland
26 programs
1
8
2
8
2
Foradil CombiPhase 41 trial
XolairPhase 41 trial
OmalizumabPhase 3Monoclonal Antibody
QAW039 150 mgPhase 31 trial
QMF149Phase 31 trial
+21 more programs
Active Trials
NCT05217810Recruiting600Est. Dec 2026
NCT05274425Recruiting600Est. Mar 2027
NCT05120986Withdrawn0Est. May 2023
+29 more trials
M&
Merck & Co.RAHWAY, NJ
17 programs
5
3
1
DuleraPhase 41 trial
MK0359Phase 23 trials
NavarixinPhase 21 trial
SCH 527123Phase 21 trial
Comparator: MK0633Phase 11 trial
+12 more programs
Active Trials
NCT01500525Completed587Est. Apr 2015
NCT00426634Completed200Est. Aug 2016
NCT01618318Completed105Est. Oct 2013
+16 more trials
Regeneron
RegeneronTARRYTOWN, NY
16 programs
1
1
6
7
DupilumabPhase 4Monoclonal Antibody
DupilumabPhase 4Monoclonal Antibody
DupilumabPhase 4Monoclonal Antibody1 trial
DupilumabPhase 4Monoclonal Antibody
Dupilumab Injectable ProductPhase 41 trial
+11 more programs
Active Trials
NCT06631677No Longer Available
NCT06226610Recruiting46Est. Dec 2026
NCT06665971Recruiting30Est. Nov 2026
+4 more trials
Sanofi
11 programs
1
2
4
1
DupilumabPhase 4Monoclonal Antibody1 trial
CiclesonidePhase 31 trial
FexofenadinePhase 31 trial
FexofenadinePhase 31 trial
Fexofenadine, Comparator = MontelukastPhase 31 trial
+6 more programs
Active Trials
NCT06099704Active Not Recruiting305Est. Apr 2026
NCT04287621Active Not Recruiting718Est. Apr 2026
NCT06623435Active Not Recruiting1,073Est. Dec 2025
+17 more trials
Genentech
9 programs
3
2
2
OmalizumabPhase 4Monoclonal Antibody
XolairPhase 4
OmalizumabPhase 3Monoclonal Antibody
omalizumabPhase 3Monoclonal Antibody
MEMP1972APhase 21 trial
+4 more programs
Active Trials
NCT01449409Active Not Recruiting3,000Est. Dec 2024
NCT01582503Completed578Est. Nov 2014
NCT00162773Terminated29Est. Sep 2009
+1 more trials
CT
1
2
1
Test preparation:Methylcholine chloroacetate for inhalationPhase 41 trial
Salmeterol Xinafoate and Fluticasone Propinate PowderPhase 31 trial
TQC2731 injectionPhase 31 trial
TQC2938 InjectionPhase 11 trial
Methacholine ChlorideN/A1 trial
+1 more programs
Active Trials
NCT05634473UnknownEst. Jun 2023
NCT05870436UnknownEst. Jun 2025
NCT06449859UnknownEst. Nov 2024
+3 more trials
Verona Pharma
4 programs
1
1
MontelukastPhase 41 trial
RPL554Phase 21 trial
Daily Monitoring of Exhaled Nitric Oxide in Asthmatic PatientsN/A1 trial
regular treatmentN/A1 trial
Active Trials
NCT01113853Completed40Est. Jan 2010
NCT00952835Unknown1,000Est. Dec 2014
NCT02427165Completed29Est. Nov 2015
+1 more trials
Allergy Therapeutics
1
1
fluticasone/salmeterol DISKUS 250/50Phase 41 trial
MepolizumabPhase 2Monoclonal Antibody1 trial
Guidelines-based asthma and rhinitis/rhinosinusitis therapyN/A1 trial
Sorting and Expression Profiling of Airway Cells From Humans (The SEARCH Study)N/A1 trial
Active Trials
NCT01383941CompletedEst. Sep 2014
NCT02791542CompletedEst. Mar 2023
NCT03292588Completed335Est. Apr 2021
+1 more trials
UP
3 programs
1
1
1
InuvairPhase 41 trial
LEVOCETIRIZINEPhase 31 trial
VR942 delivered via a Vectura Dry Powder InhalerPhase 11 trial
Active Trials
NCT02473939Completed85
NCT00160563Terminated207Est. Mar 2006
NCT00910793Completed29Est. Aug 2010
T-Therapeutics
T-TherapeuticsUK - Cambridge
2 programs
1
C1-inhibitorPhase 41 trial
A Real Life Evaluation of the Performance of a Large Volume NebulizerN/A1 trial
Active Trials
NCT03051698TerminatedEst. Oct 2019
Sandoz
1 program
1
1
fluticasone propionate/salmeterolPhase 21 trial
Active Trials
NCT00927758CompletedEst. Dec 2009
Pfizer
12 programs
2
3
3
Inhaled InsulinPhase 31 trial
RoflumilastPhase 31 trial
Tiotropium low dose QDPhase 3
IMA-638 is a biologicPhase 21 trial
Tiotropium bromidePhase 2
+7 more programs
Active Trials
NCT01033669Completed57Est. Feb 2010
NCT00971893Withdrawn0Est. Apr 2010
NCT01064804Completed20Est. Nov 2009
+11 more trials
Amgen
AmgenTHOUSAND OAKS, CA
4 programs
1
2
1
Experimental: TezepelumabPhase 3Monoclonal Antibody5 trials
LodotraPhase 21 trial
TezepelumabPhase 2Monoclonal Antibody4 trials
MEDI9929, 140 mgPhase 11 trial
Active Trials
NCT02512900Completed21Est. May 2016
NCT00686335Completed12Est. May 2010
NCT04673630Completed18Est. Sep 2022
+8 more trials
Abbott
AbbottABBOTT PARK, IL
4 programs
2
2
FlutiForm 250/10Phase 31 trial
SKP FlutiForm HFA pMDIPhase 31 trial
HumiraPhase 25 trials
medical food with EPA and GLA, vitamins and mineralsPhase 21 trial
Active Trials
NCT01078610Withdrawn0
NCT01497717Completed9Est. Oct 2016
NCT01754727Completed452Est. Oct 2015
+5 more trials
Roche
RocheSTAVANGER NORWAY, Norway
3 programs
1
1
LebrikizumabPhase 3Monoclonal Antibody1 trial
RO5036505Phase 21 trial
Integrated Care PathwayN/A1 trial
Active Trials
NCT00345267Completed180Est. Mar 2005
NCT00967590Withdrawn0Est. Aug 2010
NCT02546869Withdrawn0Est. Jun 2016
AS
3 programs
1
2
MasitinibPhase 3Small Molecule1 trial
MasitinibPhase 3Small Molecule1 trial
AB1010Phase 21 trial
Active Trials
NCT00842270Completed
NCT01449162CompletedEst. Nov 2019
NCT03771040CompletedEst. Sep 2020
DS
2 programs
2
OmalizumabPhase 3Monoclonal Antibody1 trial
OmalizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT00232050Completed327Est. May 2005
NCT00219323Completed133Est. Mar 2006
S
1 program
1
Methacholine ChloridePhase 31 trial
Active Trials
NCT02097537Completed10
E
1 program
1
rabeprazolePhase 3Small Molecule
HELP Therapeutics
HELP TherapeuticsChina - Nanjing
1 program
1
rabeprazolePhase 3Small Molecule
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
tezepelumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT07302516Not Yet RecruitingEst. Dec 2029
Arrowhead Pharmaceuticals
1
2
1
ARO-RAGEPhase 21 trial
ARO-MUC5ACPhase 1/21 trial
ARO-RAGEPhase 1/21 trial
ARO-RAGE InjectionPhase 11 trial
Active Trials
NCT05533294Completed43Est. Feb 2024
NCT05292950Terminated78Est. Nov 2024
NCT05276570Completed127Est. Apr 2025
+1 more trials
Revalesio
4 programs
2
2
RNS60Phase 21 trial
RNS60Phase 21 trial
RNS60Phase 11 trial
RNS60Phase 11 trial
Active Trials
NCT01057498CompletedEst. Jan 2011
NCT01511302CompletedEst. May 2013
NCT02497222Withdrawn
+1 more trials
Stallergenes Greer
1
1
SLIT tablets of HDM allergen extracts, 3 different dosesPhase 21 trial
SLIT tablets of house dust mite allergen extractsPhase 11 trial
Clinical, microbiological and inflammatory phenotypeN/A1 trial
Active Trials
NCT03960359Active Not RecruitingEst. Feb 2033
NCT01608243Completed94Est. Jun 2014
NCT01930461Completed386Est. Aug 2015
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
3 programs
2
JNJ-18054478Phase 21 trial
JNJ39758979Phase 21 trial
Emergency Department based asthma follow-up clinicN/A1 trial
Active Trials
NCT00140439Completed488Est. Jun 2005
NCT00530166Terminated26Est. Jul 2008
NCT00946569Completed116Est. Sep 2010
City Therapeutics
City TherapeuticsMA - Cambridge
3 programs
2
MepolizumabPhase 2Monoclonal Antibody
Pictorial asthma action planPhase 21 trial
Guidelines-based asthma and rhinitis/rhinosinusitis therapyN/A
Active Trials
NCT00136305Terminated
MediciNova
MediciNovaLA JOLLA, CA
3 programs
3
Dose Group 1Phase 21 trial
MN-221Phase 21 trial
MN-221Phase 21 trial
Active Trials
NCT00683449Terminated29Est. Mar 2009
NCT00679263Completed17Est. Jul 2008
NCT00838591Completed176Est. Mar 2012

+23 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
SanofiDupilumab
SanofiDupilumab
RegeneronDupilumab
AstraZenecabudesonide
SanofiDupilumab
SanofiDupilumab
SanofiDupilumab
AstraZenecabudesonide
Chia Tai TianQing Pharmaceutical GroupTest preparation:Methylcholine chloroacetate for inhalation
SanofiDupilumab
SanofiDupilumab
AstraZenecaBenralizumab
RegeneronDupilumab
AstraZenecaQIP intervention
SanofiDupilumab

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 9,497 patients across 50 trials

Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab

Start: Nov 2025Est. completion: Jan 20280
Phase 4Withdrawn

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

Start: Sep 2025Est. completion: Feb 2029218 patients
Phase 4Recruiting

Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)

Start: Nov 2024Est. completion: Nov 202630 patients
Phase 4Recruiting

Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma

Start: Sep 2024Est. completion: Feb 2026101 patients
Phase 4Completed

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

Start: Aug 2024Est. completion: Dec 2026250 patients
Phase 4Recruiting

Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps

Start: Aug 2024Est. completion: Dec 202560 patients
Phase 4Not Yet Recruiting

Dupilumab for Eosinophilic Esophagitis With Severe Strictures

Start: May 2024Est. completion: Dec 202630 patients
Phase 4Enrolling By Invitation

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

Start: May 2024Est. completion: Apr 20261,507 patients
Phase 4Active Not Recruiting
NCT06725641Chia Tai TianQing Pharmaceutical GroupTest preparation:Methylcholine chloroacetate for inhalation

Bioequivalence Study of Methacholine for Inhalation (pharmacodynamics)

Start: Feb 2024Est. completion: Oct 2024
Phase 4Completed

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

Start: Nov 2023Est. completion: Feb 202869 patients
Phase 4Active Not Recruiting

Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China

Start: Nov 2022Est. completion: Jan 202444 patients
Phase 4Completed

BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

Start: Oct 2022Est. completion: Jul 202445 patients
Phase 4Completed

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP

Start: Sep 2022Est. completion: Dec 202620 patients
Phase 4Recruiting
NCT05440097AstraZenecaQIP intervention

CARE FOR ALL:an Evaluation of an Asthma QIP

Start: Jul 2022Est. completion: Sep 20241,500 patients
Phase 4Completed

Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis

Start: Jun 2022Est. completion: Jan 202521 patients
Phase 4Completed
NCT04380038RegeneronDupilumab Injectable Product

Viral Infection in Asthma (VIA) Study

Start: May 2022Est. completion: Dec 202660 patients
Phase 4Recruiting

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

Start: Apr 2022Est. completion: Oct 2025287 patients
Phase 4Completed

Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma

Start: Feb 2022Est. completion: Jun 202315 patients
Phase 4Completed

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

Start: Dec 2021Est. completion: Aug 20291,324 patients
Phase 4Recruiting

FAsenra Safety Trial in India

Start: Nov 2021Est. completion: Jul 2023139 patients
Phase 4Completed

Predictive Signature of Benralizumab Response

Start: Oct 2021Est. completion: Nov 2026220 patients
Phase 4Recruiting

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

Start: Sep 2021Est. completion: Dec 2024360 patients
Phase 4Completed
NCT04997304TevaAirDuo Digihaler

Teva Asthma Predictive Analytics Study

Start: Jul 2021Est. completion: Dec 2023100 patients
Phase 4Completed

Dupilumab in the Treatment of Keloids

Start: May 2021Est. completion: Mar 202544 patients
Phase 4Completed

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

Start: Apr 2021Est. completion: Aug 202254 patients
Phase 4Completed
NCT04677959TevaFluticasone propionate/salmeterol

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

Start: Feb 2021Est. completion: Mar 2022427 patients
Phase 4Completed

Actigraphy Improvement With Voxelotor (ActIVe) Study

Start: Dec 2020Est. completion: Sep 202225 patients
Phase 4Completed

A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma

Start: Oct 2020Est. completion: Oct 2021333 patients
Phase 4Completed

A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma

Start: Aug 2020Est. completion: Nov 2023202 patients
Phase 4Completed

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Start: Jul 2020Est. completion: Jan 2023170 patients
Phase 4Completed

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

Start: Jul 2020Est. completion: Jun 202152 patients
Phase 4Completed

A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma

Start: Jul 2020Est. completion: Jul 202340 patients
Phase 4Completed

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

Start: Jun 2020Est. completion: Aug 2023109 patients
Phase 4Completed

The Effects of Dupilumab on Allergic Contact Dermatitis

Start: Dec 2019Est. completion: Jul 202617 patients
Phase 4Active Not Recruiting

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

Start: Oct 2019Est. completion: Oct 202675 patients
Phase 4Active Not Recruiting

Benralizumab Exacerbation Study

Start: Sep 2019Est. completion: Apr 2024157 patients
Phase 4Completed

SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"

Start: Aug 2019Est. completion: Oct 2021188 patients
Phase 4Completed

The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

Start: Nov 2018Est. completion: Dec 202234 patients
Phase 4Completed

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

Start: Jul 2018Est. completion: Sep 202072 patients
Phase 4Terminated
NCT02937168TevaReslizumab

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

Start: May 2017Est. completion: May 20175 patients
Phase 4Terminated

C1-inhibitor in Allergic ASThma Patients

Start: Nov 2016Est. completion: Oct 2019
Phase 4Terminated

A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD

Start: Jun 2015Est. completion: Nov 2016776 patients
Phase 4Completed

Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence

Start: Mar 2014Est. completion: Jul 201750 patients
Phase 4Completed

Targeted Small Airways Therapy in Persistent Asthma

Start: Oct 2013Est. completion: Jun 201826 patients
Phase 4Completed

Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start: Aug 2013Est. completion: Jan 2014152 patients
Phase 4Completed

Dose-Response of Salmeterol in Children

Start: Aug 2013Est. completion: Jul 201410 patients
Phase 4Completed
NCT01741285TevaBeclomethasone

Effects of QVAR in Smokers With Asthma

Start: Apr 2013Est. completion: Dec 201540 patients
Phase 4Completed

Effects of Symbicort on the Ventilatory Kinematics

Start: Mar 2012Est. completion: Sep 20129 patients
Phase 4Terminated
NCT00997477NovartisForadil Combi

Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics

Start: Jun 20100
Phase 4Withdrawn

Effect of Montelukast on Remodelling Markers in Asthmatic Children

Start: Feb 2010Est. completion: Apr 201330 patients
Phase 4Completed

Related Jobs in Respiratory

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

82 late-stage (Phase 3) programs — potential near-term approvals
7 actively recruiting trials targeting 9,497 patients
30 companies competing in this space